Marksans Pharma Limited (IN:MARKSANS)
:MARKSANS
Want to see IN:MARKSANS full AI Analyst Report?
Top Page
Marksans Pharma Limited
(MARKSANS)
Select Model
Select Model
Rating:71Outperform
Price Target:
₹174.00
▼(-4.42% Downside)
Action:UpgradedDate:02/04/26
The score is driven mainly by strong financial performance—solid growth, improving margins, and low leverage—tempered by softer operating cash flow conversion. Technical indicators are mixed with negative MACD and longer-term weakness versus the 200-day average, while valuation appears reasonable but with a low dividend yield.
Positive Factors
Strong revenue growth and margins
Marksans' ~20.45% revenue growth coupled with a 56.38% gross margin and 14.51% net margin indicate durable demand and effective cost control across its product mix. Sustained high margins support reinvestment in manufacturing, regulatory filings and commercial expansion, bolstering earnings resilience over the medium term.
Negative Factors
Weak operating cash flow conversion
Operating cash flow declined 10.28% and OCF converts only ~54% of reported net income, indicating weaker cash realization from operations. If persistent, this constrains self-funding of working capital and regulatory filings, potentially forcing more external financing or slower product rollouts over time.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong revenue growth and margins
Marksans' ~20.45% revenue growth coupled with a 56.38% gross margin and 14.51% net margin indicate durable demand and effective cost control across its product mix. Sustained high margins support reinvestment in manufacturing, regulatory filings and commercial expansion, bolstering earnings resilience over the medium term.
Read all positive factors
Marksans Pharma Limited (MARKSANS) vs. iShares MSCI India ETF (INDA)
Market Cap
₹84.99B
Dividend Yield0.44%
Average Volume (3M)99.03K
Price to Earnings (P/E)18.0
Beta (1Y)1.48
Revenue Growth13.29%
EPS Growth-2.17%
CountryIN
Employees1,141
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - General
Share Statistics
EPS (TTM)2.50
Shares Outstanding453,163,760
10 Day Avg. Volume119,310
30 Day Avg. Volume99,030
Financial Highlights & Ratios
PEG Ratio1.24
Price to Book (P/B)4.08
Price to Sales (P/S)3.83
P/FCF Ratio298.02
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)10.6
Revenue Forecast (FY)₹33.60B
Marksans Pharma Limited Business Overview & Revenue Model
Company Description
Marksans Pharma Limited, together with its subsidiaries, engages in the research and development, manufacturing, marketing, distribution, and sale of generic pharmaceutical formulations worldwide. The company offers products in the analgesics, ben...
How the Company Makes Money
Marksans primarily makes money by selling pharmaceutical and healthcare products, with revenue largely derived from (1) finished-dosage generic formulations sold into domestic and export markets and (2) OTC products sold through consumer healthcar...
Marksans Pharma Limited Financial Statement Overview
Summary
Income Statement
85
Very Positive
Balance Sheet
80
Positive
Cash Flow
75
Positive
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 27.31B | 26.23B | 21.77B | 18.52B | 14.80B | 13.68B |
| Gross Profit | 15.37B | 14.79B | 11.03B | 9.31B | 7.32B | 7.50B |
| EBITDA | 5.62B | 5.29B | 5.09B | 3.99B | 3.01B | 3.46B |
| Net Income | 3.52B | 3.81B | 3.14B | 2.66B | 1.85B | 2.39B |
Balance Sheet | ||||||
| Total Assets | 34.42B | 32.40B | 26.81B | 21.90B | 16.40B | 12.28B |
| Cash, Cash Equivalents and Short-Term Investments | 6.71B | 7.05B | 7.00B | 7.19B | 3.47B | 2.12B |
| Total Debt | 3.32B | 3.22B | 2.44B | 1.23B | 1.11B | 341.02M |
| Total Liabilities | 7.28B | 7.50B | 5.95B | 4.25B | 4.17B | 3.23B |
| Stockholders Equity | 26.88B | 24.67B | 20.65B | 17.45B | 12.02B | 8.86B |
Cash Flow | ||||||
| Free Cash Flow | 19.97M | 337.45M | 215.69M | 1.84B | 529.27M | 1.32B |
| Operating Cash Flow | 751.86M | 2.07B | 2.30B | 2.37B | 992.57M | 1.79B |
| Investing Cash Flow | -364.77M | -490.09M | -1.41B | -2.59B | -416.86M | -448.96M |
| Financing Cash Flow | -528.77M | -651.46M | -687.27M | 1.98B | 795.11M | -152.86M |
Marksans Pharma Limited Technical Analysis
Positive
182.05
Price Trends
173.61
Positive
177.37
Positive
188.45
Negative
Market Momentum
2.20
Negative
58.81
Neutral
90.58
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:MARKSANS, the sentiment is Positive. The current price of 182.05 is above the 20-day moving average (MA) of 169.46, above the 50-day MA of 173.61, and below the 200-day MA of 188.45, indicating a neutral trend. The MACD of 2.20 indicates Negative momentum. The RSI at 58.81 is Neutral, neither overbought nor oversold. The STOCH value of 90.58 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:MARKSANS.
Marksans Pharma Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | ₹84.99B | 18.03 | ― | 0.44% | 13.29% | -2.17% | |
71 Outperform | ₹79.10B | 38.14 | ― | 4.73% | -12.98% | -21.81% | |
69 Neutral | ₹217.95B | 40.22 | ― | 0.69% | 11.01% | 38.67% | |
68 Neutral | ₹1.06T | 45.14 | ― | 0.87% | 5.08% | -8.91% | |
63 Neutral | ₹401.66B | 35.44 | ― | 2.16% | 2.59% | 18.83% | |
61 Neutral | ₹286.21B | 27.13 | ― | 1.07% | 6.70% | 20.25% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
IN:MARKSANS
Marksans Pharma Limited
187.55
-30.68
-14.06%
IN:CIPLA
Cipla Ltd
1,316.65
-216.61
-14.13%
IN:GLAND
Gland Pharma Ltd.
1,737.15
351.71
25.39%
IN:GLAXO
GlaxoSmithKline Pharmaceuticals Limited
2,371.00
-550.43
-18.84%
IN:PFIZER
PFIZER LIMITED
4,764.15
587.49
14.07%
IN:SANOFI
Sanofi India Limited
3,434.55
-2,325.90
-40.38%
Marksans Pharma Limited Corporate Events
Marksans Pharma to Join Investec India Promoter & Founder Conference 2026
Mar 10, 2026
Marksans Pharma Limited has notified the stock exchanges that its officials will participate in the Investec India Promoter Founder Conference 2026, scheduled for March 11, 2026, as a physical event at the Trident BKC in Mumbai. The company clari...
Marksans Pharma Releases Q3 and 9M FY26 Investor Presentation
Feb 5, 2026
Marksans Pharma Limited has released its investor presentation for the third quarter and nine months ended FY26, in compliance with SEBI’s listing and disclosure regulations. The presentation, now shared with stock exchanges, provides update...
Marksans Pharma Expands Global Footprint With New Subsidiaries in Europe and Canada
Jan 27, 2026
Marksans Pharma Limited has strengthened its international footprint by incorporating two new wholly owned subsidiaries: Marksans Pharma (Europe) Limited in Ireland and Marksans (Canada) Inc. in Canada. Both entities, newly formed and without prio...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.